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Long and short term side effects of antiretroviral drugs are not fully understood yet. Here a case of reversible blood
count changes following post exposure prophylaxis with tenofovir/emtricitabin and lopinavir/ritonavir is reported.
We propose that antiretroviral drugs used in post exposure prophylaxis may have a significant impact on
hematopoiesis.
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Needle prick injury is common in clinical practice. In
order to prevent HIV infection, post exposure prophy-
laxis (PEP) is considered in situations with potential risk
of infection [1,2]. Long and short term side effects of the
drugs used are not fully understood yet. Here, we report
a case of reversible leukopenia and thrombocytopenia
following a 28 days course of post exposure prophylaxis
with tenofovir/emtricitabin and lopinavir/ritonavir.
Case presentation
A 56 years old male patient presented after occupational
needle prick injury. Index patient could not be determined
and PEP was started within 28 hours with lopinavir
400 mg/ritonavir 100 mg BD and tenofovir 245 mg/emtri-
citabin 200 mg QD and was continued for 28 days. Ser-
ology for HIV, HCV, HBV as well as parameters for blood
count (leukocytes 4.6 Gpt/l, thrombocytes 146 Gpt/l), liver
and renal function tests were unremarkable. Hepatitis B
vaccination was administered. Past medical history re-
vealed coronary heart disease, hypertension and the
patient reported known marginal reduction of platelets
in absence of any hemic disease. The concurrent medi-
cation consisted of ramipril 5 mg QD, acetylsalicylacid
100 mg QD and simvastatin 40 mg QD. The statin was
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article, unless otherwise stated.Antiretroviral post exposure treatment was clinically
well tolerated and the patient reported no symptoms of
rash or gastrointestinal side effects. Control of laboratory
parameters on day 19 after initiation of PEP showed a
slight decrease in WBC to 4.0 Gpt/l. Investigation on
day 33 (5 days after the end of PEP) showed bicytopenia
with leukopenia 2.0 Gpt/l and thrombocytopenia 97 Gpt/l.
A second control on day 40 revealed a return to a normal
blood count and no alterations of differential blood count
(neutrophil granulocytes 3.61 Gpt/l, lymphocytes 1.46
Gpt/l, monocytes 0.39 Gpt/l, eosinophil granulocytes 0.06
Gpt/l, basophil granulocytes 0.02 Gpt/l). Serum electro-
phoresis was unremarkable (total protein 70.4 g/l, albumin
66.9%, alpha-1-globulin 3.6%, alpha-2-globulin 8.4%, beta-
globulin 9.7%, gamma-globulin 11.4%) and determination
of ANA and pANCA as well as folic acid and vitamin B
12 levels revealed normal values. There was no evidence
of blood count changes during follow up over 6 months
and the patient remained sero-negative for HIV and HCV.
After stratification of benefits and risks, no further inva-
sive clarification of pathogenicity was initiated.Conclusions
Cytopenia such as anemia, thrombocytopenia, neutropenia
or lymphopenia is a known effect of HIV and AIDS status
is an identified risk factor. A recent Korean publication
pointed out the impact of HIV alone on hematologic mani-
festations. In this study cytopenia was shown to be revers-
ible with antiretroviral treatment [3]. Thrombocytopenia or
leukopenia following antiretroviral post exposure therapyentral Ltd. This is an Open Access article distributed under the terms of the
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yet. In a retrospective study leukopenia was associated
with lopinavir/ritonavir [4]. A thorough review revealed a
single case of thrombocytopenia associated with lopinavir/
ritonavir [5]. As a mechanism of pathogenicity autoimmune
causes can be discussed for thrombocytopenia in our case.
Since ANA and ANCA were tested negative this hypothesis
is less convincible. As leukopenia emerged simultaneously
to thrombocytopenia a direct impact on hematopoiesis
seems more plausible. Thrombocytopenia was described
for other protease inhibitors such as saquinavir, but to this
date no feasible hypothesis for pathogenicity is available
[6]. Based on previous observations and this case report
we propose that antiretroviral drugs used in PEP may have
a direct impact on hematopoiesis. The precise mechanism
should be further investigated.
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